Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978017 | 0.77 | HDAC1 (0.44) | KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL31143494 | 0.77 | HDAC1 (0.44) | KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL17933911 | 0.76 | GRIN2D (0.51) | LMNARAD52RECQLMAPTGAA | |
| SCHEMBL31143329 | 0.76 | GRIN2D (0.51) | LMNARAD52RECQLMAPTGAA | |
| SCHEMBL31143411 | 0.75 | RAD52 (0.45) | KDM4ELMNARAD52RECQLMAPT | |
| SCHEMBL31143467 | 0.74 | HTT (0.54) | KDM4ERAD52RECQLMAPTSMN1; SMN2 | |
| SCHEMBL31143330 | 0.72 | RAD52 (0.47) | KDM4ELMNARAD52RECQLMAPT | |
| SCHEMBL31143408 | 0.71 | RAD52 (0.44) | KDM4ELMNARAD52RECQLMAPT | |
| SCHEMBL31143551 | 0.70 | RAD52 (0.48) | KDM4ELMNARAD52RECQLMAPT | |
| SCHEMBL2853594 | 0.70 | P2RX3 (0.53) | KDM4EABL1LMNAP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385948-B1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LTD (IN) | 2017-10-04 | — | — | EP | disclosed |
| US-8822484-B2 | Fused thiazolo and oxazolo pyrimidinones | TORRENT PHARMACEUTICALS LIMITED (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20130331406-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2013-12-12 | — | — | US | disclosed |
| US-8541430-B2 | Fused thiazolo and oxazolo pyrimidinones | TORRENT PHARMACEUTICALS LIMITED (IN) | 2013-09-24 | — | — | US | disclosed |
| EP-2385948-A1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | Torrent Pharmaceuticals Limited (IN) | 2011-11-16 | — | — | EP | disclosed |
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| WO-2011045811-A1 | FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331406-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, TYMS, UGT1A8 | KDM4E 4251/4885ABL1 2625/4885LMNA 3820/4885 |
| US-20110130414-A1 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES | TPMT, ABCG2, TALDO1 | KDM4E 4481/4885ABL1 1334/4885LMNA 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.